Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
$1.24
-$0.17(-7.61%)
At close: 4:00 PM EST
$1.24
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.79 - $6.98
Previous CloseN/A
Volume358.39K
Average Volume (3M)2.05M
Market Cap
$55.08M
Enterprise Value$84.93M
Total Cash (Recent Filing)$8.90M
Total Debt (Recent Filing)$34.70M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Dec 18, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding44,419,530
10 Day Avg. Volume1,203,280
30 Day Avg. Volume2,049,237
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.36
Price to Sales (P/S)0.00
P/FCF Ratio-1.44
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue50.69
Enterprise Value/Gross Profit77.72
Enterprise Value/Ebitda-1.76
Forecast
1Y Price Target
$4.00Price Target Upside222.58% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Competitive PositioningManagement is confident in Lytenava's ability to compete effectively in both countries given its regulatory approval and price advantage.
European Market ExpansionExpansion into other European countries, starting in Austria and the Netherlands, could drive further growth.
Initial Sales PerformanceInitial sales of Lytenava encouraging, generating a decent quarterly revenue since its launch in Germany and UK.
Bears Say
Clinical TrialsThe NORSE 8 study failed to meet its primary endpoint.
Financial StabilityFinancing continues to be a major overhang on the name; with cash guidance only for the next 3 months, there are serious doubts on the company's ability to get ONS-5010 approved in the U.S.
Regulatory ChallengesThe FDA issued a CRL for the BLA resubmission of ONS-5010 in wet AMD, requiring additional evidence of efficacy for approval.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.79 and its highest was $6.98 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $55.08M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2025 which is in 48 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.088.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 44,419,530 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went up 14.085%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
Outlook Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (222.58% Upside)
$4.00 (222.58% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.45%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$4.00
▲(222.58% Upside)
Technical Analysis
Ownership Overview
31.77% Insiders
3.52% Mutual Funds
0.05% Other Institutional Investors
61.88% Public Companies and
Individual Investors